MA29133B1 - Nouvelle combinaison - Google Patents

Nouvelle combinaison

Info

Publication number
MA29133B1
MA29133B1 MA30001A MA30001A MA29133B1 MA 29133 B1 MA29133 B1 MA 29133B1 MA 30001 A MA30001 A MA 30001A MA 30001 A MA30001 A MA 30001A MA 29133 B1 MA29133 B1 MA 29133B1
Authority
MA
Morocco
Prior art keywords
new combination
neu
molecule
vaccine targeting
quinazolineamine
Prior art date
Application number
MA30001A
Other languages
English (en)
Inventor
Claudine Elvire Marie Bruck
Catherine Marie Ghislaine Gerard
Original Assignee
Glaxosmithkline Biolog Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Biolog Sa filed Critical Glaxosmithkline Biolog Sa
Publication of MA29133B1 publication Critical patent/MA29133B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001103—Receptors for growth factors
    • A61K39/001106—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ErbB4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'INVENTION CONCERNE UN PROCÉDÉ DE TRAITEMENT DU CANCER QUI CONSISTE À ADMINISTRER UNE 4-QUINAZOLINEAMINE ET UN VACCIN CIBLANT LA MOLÉCULE HER-2/NEU, ET UNE COMBINAISON PHARMACEUTIQUE QUI RENFERME DES 4-QUINAZOLINEAMINES ET UN VACCIN CIBLANT LA MOLÉCULE HER-2/NEU.
MA30001A 2004-12-10 2007-06-18 Nouvelle combinaison MA29133B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0427131.8A GB0427131D0 (en) 2004-12-10 2004-12-10 Novel combination

Publications (1)

Publication Number Publication Date
MA29133B1 true MA29133B1 (fr) 2008-01-02

Family

ID=34073534

Family Applications (1)

Application Number Title Priority Date Filing Date
MA30001A MA29133B1 (fr) 2004-12-10 2007-06-18 Nouvelle combinaison

Country Status (15)

Country Link
US (1) US20100028414A1 (fr)
EP (1) EP1824509A2 (fr)
JP (1) JP2008523017A (fr)
KR (1) KR20070098857A (fr)
CN (1) CN101115499A (fr)
AU (1) AU2005313439A1 (fr)
BR (1) BRPI0518619A2 (fr)
CA (1) CA2589981A1 (fr)
GB (1) GB0427131D0 (fr)
IL (1) IL183448A0 (fr)
MA (1) MA29133B1 (fr)
MX (1) MX2007006927A (fr)
NO (1) NO20072668L (fr)
RU (1) RU2007120462A (fr)
WO (1) WO2006061253A2 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7972602B2 (en) * 2006-08-11 2011-07-05 Dendreon Corporation Promiscuous HER-2/Neu CD4 T cell epitopes
CA2675366A1 (fr) * 2007-01-18 2008-07-24 University Of Southern California Polymorphismes geniques predictifs d'une bitherapie a base de tki
KR20110044905A (ko) * 2008-08-15 2011-05-02 메리맥 파마슈티컬즈, 인크. 치료제에 대한 세포의 반응을 예측하는 방법 및 시스템
WO2010023216A1 (fr) 2008-08-28 2010-03-04 Glaxosmithkline Biologicals S.A. Vaccin
WO2012018260A1 (fr) * 2010-08-05 2012-02-09 Universiteit Utrecht Holding B.V. Thérapie immunitaire ciblant le récepteur du facteur de croissance épidermique
AU2016232834B2 (en) * 2015-03-19 2020-01-02 Aerovironment, Inc. Mounting system for mechanical-shock resistant printed circuit board (PCB)
RU2603943C1 (ru) * 2016-02-01 2016-12-10 Индивидуальный предприниматель Михайлов Олег Ростиславович КРИСТАЛЛИЧЕСКАЯ γ-МОДИФИКАЦИЯ N-{3-ХЛОР-4-[(3-ФТОРБЕНЗИЛ)ОКСИ] ФЕНИЛ}-6-[5-({[2-(МЕТАНСУЛЬФОНИЛ)ЭТИЛ]АМИНО}МЕТИЛ)-2-ФУРИЛ]-4-ХИНАЗОЛИНАМИНА БИС (4-МЕТИЛБЕНЗОЛСУЛЬФОНАТА) МОНОГИДРАТА, СПОСОБ ЕЁ ПОЛУЧЕНИЯ И ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ НА ЕЁ ОСНОВЕ
US20210121518A1 (en) * 2018-02-15 2021-04-29 Board of Supervisors for the University of Louisiana System Her2-targeted peptidomimetics grafted onto multicyclic peptide scaffolds and methods and uses

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4436727A (en) * 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
US4866034A (en) * 1982-05-26 1989-09-12 Ribi Immunochem Research Inc. Refined detoxified endotoxin
US4877611A (en) * 1986-04-15 1989-10-31 Ribi Immunochem Research Inc. Vaccine containing tumor antigens and adjuvants
US4912094B1 (en) * 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
US5759551A (en) * 1993-04-27 1998-06-02 United Biomedical, Inc. Immunogenic LHRH peptide constructs and synthetic universal immune stimulators for vaccines
US5856462A (en) * 1996-09-10 1999-01-05 Hybridon Incorporated Oligonucleotides having modified CpG dinucleosides
GB9717953D0 (en) * 1997-08-22 1997-10-29 Smithkline Beecham Biolog Vaccine
RS49779B (sr) * 1998-01-12 2008-06-05 Glaxo Group Limited, Biciklična heteroaromatična jedinjenja kao inhibitori protein tirozin kinaze
WO2000044899A1 (fr) * 1999-01-29 2000-08-03 Corixa Corporation Proteines de fusion her-2/neu
CA2413134C (fr) * 2000-06-30 2010-05-11 Glaxo Group Limited Composes ditosylates de quinazoline
US7141576B2 (en) * 2001-01-16 2006-11-28 Smithkline Beecham (Cork) Limited Cancer treatment method
WO2005011607A2 (fr) * 2003-08-01 2005-02-10 Smithkline Beecham Corporation Traitement des cancers exprimant p95erbb2
SG135193A1 (en) * 2003-08-18 2007-09-28 Pfizer Prod Inc Dosing schedule for erbb2 anticancer agents

Also Published As

Publication number Publication date
NO20072668L (no) 2007-09-04
MX2007006927A (es) 2007-06-26
CN101115499A (zh) 2008-01-30
WO2006061253A2 (fr) 2006-06-15
WO2006061253A3 (fr) 2006-11-16
RU2007120462A (ru) 2009-01-20
US20100028414A1 (en) 2010-02-04
IL183448A0 (en) 2007-09-20
CA2589981A1 (fr) 2006-06-15
KR20070098857A (ko) 2007-10-05
EP1824509A2 (fr) 2007-08-29
BRPI0518619A2 (pt) 2008-11-25
JP2008523017A (ja) 2008-07-03
GB0427131D0 (en) 2005-01-12
AU2005313439A1 (en) 2006-06-15

Similar Documents

Publication Publication Date Title
DK1346041T3 (da) Terapeutiske midler og fremgangsmåder til anvendelse deraf til behandling af en amyloidogen sygdom
CR20240003A (es) Restos de administración terapéutica novedosos y usos de estos
MA42239B1 (fr) Nouveaux dérivés d'hydroxyester, leur procédé de préparation et compositions pharmaceutiques les contenant
DE602004027936D1 (de) Tocopherolmodifizierte therapeutische arzneimittelverbindung
EP1819227A4 (fr) Formulation pharmaceutique de decitabine
UY30377A1 (es) Inhibidores triciclicos fusionados de sulfonamida de gama-secretasa
BR9813656A (pt) Aminas como agentes farmacêuticos
BR0212617A (pt) Compostos de pirazolila substituìdo para o tratamento de inflamação
EA200500289A1 (ru) Арилзамещенные бензимидазолы и их использование в качестве блокаторов натриевых каналов
UY26456A1 (es) Compuestos que fijan la estructura g-cuadruplex de los telomeros, triazinas de aplicación de dichos compuestos, la utilización de dichos compuestos como productos farmacéuticos y las asociaciones terapéuticas que los incluyen.
GT200500060A (es) Compuestos de imidazol para el tratamiento de trastornos neurodegenerativos
DOP2003000639A (es) Pirazolopiridinas substituidas con carbamato
BR0212613A (pt) Compostos de indazol substituìdos para o tratamento de inflamação
CY1111359T1 (el) Μεμαντινη για την θεραπεια ηπιας εως μετριας ασθενειας alzheimer
BR0207883A (pt) Composições de medicamentos à base de anticolenérgicos e inibidores de pde-iv
UY28376A1 (es) Agentes terapéuticos
EA200401526A1 (ru) Новые соединения и их применение
BRPI0413245A (pt) compostos heteroarila de 6 membros para o tratamento de distúrbio neurodegenerativos
BRPI0408863A (pt) composto, composição farmacêutica, método para tratar doenças, e, uso de um composto.
DK1670903T3 (da) Behandling af neurodegenerative sygdomme
IS6558A (is) Blandaðar sjúkdómsmeðferðir með æðaskaðandi virkni
DOP2005000050A (es) Métodos para tratar la esquizofrenia y/o las anomalías de glucorregulación
MA31742B1 (fr) Derives de l'indol-2-one disubstitues en 3, leur preparation et leur application en therapeutique
NO20072668L (no) Ny kombinasjon
EA200970436A1 (ru) Соединения карбамата для лечения депрессии